Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemafibrate pharmacokinetics and safety study in primary biliary cholangitis with and without compensated cirrhosis
jRCT2071240023Phase 1Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of pemafibrate in primary biliary cholangitis (PBC) (2 arms), sponsored by Kowa Company, Ltd. Primary endpoints: Pharmacokinetic parameters after a single dose of pemafibrate, Trough concentrations after multiple dosing of pemafibrate and 1 more. Started Jul 2024; status: completed.
02
Drugs
pemafibrate
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on jRCT2071240023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240023.